PA
GNTX icon

PharVision Advisers’s Gentex GNTX Stock Holding History

PharVision Advisers’s Portfolio GNTX Stock Details GNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,353
Closed -$357K – 328
2025
Q4 		$357K Buy
+15,353
New +$370K 0.18% 180
2025
Q2 		– Sell
-11,512
Closed -$268K – 339
2025
Q1 		$268K Buy
+11,512
New +$294K 0.37% 118

Other funds holding GNTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's GNTX Position: Q1 2026 in Review

PharVision Advisers sold out of Gentex (GNTX) in Q1 2026, closing a stake of 15,353 shares — an estimated $357K sold.

PharVision Advisers first reported a position in GNTX in Q1 2025 and held it in 2 quarters. The position peaked at $357K in Q4 2025. 502 funds tracked by Wall St. Rank hold GNTX as of Q1 2026.

  • PharVision Advisers reported no remaining Gentex position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 15,353 Gentex shares in Q1 2026, an estimated $357K.
  • PharVision Advisers first reported a position in Gentex in Q1 2025 and held it in 2 quarters.
  • PharVision Advisers's Gentex position peaked at $357K in Q4 2025.
  • 502 funds tracked by Wall St. Rank held Gentex as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.